HF
RVMD icon

HRT Financial’s Revolution Medicines RVMD Stock Holding History

HRT Financial’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,192
Closed -$1.13M – 4605
2025
Q4 		$891K Sell
11,192
-67,929
-86% -$4.45M ﹤0.01% 1786
2025
Q3 		$3.69M Sell
79,121
-607,305
-88% -$23.8M 0.01% 814
2025
Q2 		$25.3M Buy
686,426
+662,719
+2,795% +$25.5M 0.11% 123
2025
Q1 		$838K Buy
+23,707
New +$962K 0.01% 1199
2024
Q2 		– Sell
-64,053
Closed -$2.06M – 2970
2024
Q1 		$2.06M Buy
+64,053
New +$1.9M 0.01% 554
2023
Q1 		– Sell
-98,186
Closed -$2.34M – 3102
2022
Q4 		$2.34M Buy
+98,186
New +$2.09M 0.03% 517
2022
Q3 		– Sell
-94,448
Closed -$1.84M – 3402
2022
Q2 		$1.84M Buy
94,448
+29,062
+44% +$566K 0.02% 606
2022
Q1 		$1.67M Buy
65,386
+37,154
+132% +$809K 0.01% 721
2021
Q4 		$710K Buy
+28,232
New +$796K ﹤0.01% 1493

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HRT Financial's RVMD Position: Q1 2026 in Review

HRT Financial sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 11,192 shares — an estimated $1.13M sold.

HRT Financial first reported a position in RVMD in Q4 2021 and held it in 9 quarters. The position peaked at $25.3M in Q2 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • HRT Financial reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 11,192 Revolution Medicines shares in Q1 2026, an estimated $1.13M.
  • HRT Financial first reported a position in Revolution Medicines in Q4 2021 and held it in 9 quarters.
  • HRT Financial's Revolution Medicines position peaked at $25.3M in Q2 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.